Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Taysha Gene Therapies, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 49 | 48 | −1 |
| Shares | 18.3M | 19.4M | +1.11M (+6.1%) |
| Value | $388.6M | $361.9M | −$26.6M (−6.9%) |
New holders (4)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sands Capital Ventures, LLC | 724,873 | $13.5M | 2.04% |
| Goldman Sachs Group Inc | 12,099 | $225.0K | 0.00% |
| SG Americas Securities, LLC | 9,168 | $171.0K | 0.00% |
| Macquarie Group Ltd | 2,210 | $41.0K | 0.00% |
Sold out (5)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Sands Capital Management, LLC | 724,873 | $15.4M |
| Octagon Capital Advisors LP | 320,440 | $6.79M |
| Pura Vida Investments, LLC | 33,822 | $717.0K |
| Millennium Management LLC | 30,165 | $639.0K |
| D. E. Shaw & Co., Inc. | 11,448 | $243.0K |